//www.makeeyeware.comInsight
//www.makeeyeware.comTaplow
//www.makeeyeware.comKnowledge
  • News
  • Cases
  • Downloads
The Taplow Group – EMEA Region 2021 Business Outlook
22.12.2020

The Taplow Group – EMEA Region 2021 Business Outlook

当我们走向动荡的一年一个的结束d look towards 2021, Taplow partners across the globe have combined to give local and regional...
The Taplow Group – AMERICAS Region 2021 Business Outlook
21.12.2020

The Taplow Group – AMERICAS Region 2021 Business Outlook

当我们走向动荡的一年一个的结束d look towards 2021. Taplow partners across the globe have combined to give you local and...
The Taplow Group – APAC Region 2021 Business Outlook
21.12.2020

The Taplow Group – APAC Region 2021 Business Outlook

当我们走向动荡的一年一个的结束d look towards 2021. Taplow partners across the globe have combined to give you local and...
1 2 3 4 5 6 7 8 9 10 Last

CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

CEO FOR LOGISTICS:

情境:全球最大的操作ogistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contactSangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here